Concord Biotech Share Price
29 Oct, 2026 1:14 PM (IST)
Concord Biotech Performance
- Today's Low
- ₹1,227
- Today's High
- ₹1,281
- 52 Week Low
- ₹987
- 52 Week High
- ₹1,615
- Open Price₹1,265
- Previous Close₹1,269
- Volume106,258
- 50 DMA₹1,378.50
- 100 DMA₹1,362.50
- 200 DMA₹1,359.10
Concord Biotech Chart
Investment Returns
- Over 1 Month -11.64%
- Over 3 Month -2.03%
- Over 6 Month + 14.79%
- Over 1 Year -14.06%
Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!
Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 45.6
- PEG Ratio
- -3.6
- Market Cap Cr
- 12,874
- P/B Ratio
- 6.2
- Average True Range
- 61.2
- EPS
- 27
- Dividend Yield
- 0.6
- MACD Signal
- -38.3
- RSI
- 40.77
- MFI
- 41.74
Latest Stock News Updates
Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026
- BSE India
- 18 hours 42 minutes ago
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.
- BSE India
- 22 hours 17 minutes ago
Press release - For the Second quarter and half year ended on September 30, 2026
- BSE India
- 22 hours 26 minutes ago
Concord Biotech Financials
Concord Biotech Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹1,341.00
- 50 Day
- ₹1,378.50
- 100 Day
- ₹1,362.50
- 200 Day
- ₹1,359.10
Resistance and Support
- R3 1,383.90
- R2 1,358.40
- R1 1,313.50
- S1 1,243.10
- S2 1,217.60
- S3 1,172.70
Concord Biotech Corporate Actions - Bonus, Splits, Dividends
About Concord Biotech
Concord Biotech Ltd. is leading biotechnology company in India, specializing in development & manufacturing of fermentation based biopharmaceuticals. Established in 2000, company has grown to become significant player in global biotech industry, with strong focus on immunosuppressants, oncology, & nephrology products. Concord Biotech's state of the art manufacturing facilities are designed to meet international quality standards, enabling company to supply its products to over 70 countries worldwide. company's dedication to innovation, research, & development has made it trusted partner in global healthcare industry.
diversified clientele: 200 clients in more than 70 countries use company's API & formulation solutions. long-term supply agreements with these clients accounted for 14.06%, 12.45%, & 12.56% of their revenues in FY21, FY22, & FY23.
R&D: Concord maintains specialized R&D facilities for formulations & APIs in Dholka & Valthera. Both have Indian DSIR's approval. Their R&D units employed 148 people as of March 31, 2022, making up 11.99% of their total number of permanent employees.
Domestic Presence: They sell range of 27 products in India, including immunosuppressants, nephrology medications, & anti-infective medications used in critical care. In India, they are present in 20 states & 5 union territories.
View More- NSE Symbol
- CONCORDBIO
- BSE Symbol
- 543960
- Executive Director,Joint Managing Director,Chief Executive Officer
- ANKUR VAID
- ISIN
- INE338H01029
Similar Stocks to Concord Biotech
Popular Stocks
Concord Biotech FAQs
Concord Biotech share price is ₹1,230 As on 29 October, 2026 | 13:09
The Market Cap of Concord Biotech is ₹12874.1 Cr As on 29 October, 2026 | 13:09
The P/E ratio of Concord Biotech is 45.6 As on 29 October, 2026 | 13:09
The PB ratio of Concord Biotech is 6.2 As on 29 October, 2026 | 13:09
The 52 week High & Low of Concord Biotech is ₹1615/₹987 respectively As on 29 October, 2026 | 13:09
Consider company's product pipeline & growth prospects in biotech industry before investing.
Key metrics include revenue from key therapeutic areas, R&D investment, & profit margins.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Concord Biotech share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.